Welcome to our dedicated page for Biomarin Pharmaceutical SEC filings (Ticker: BMRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioMarin Pharmaceutical Inc. (BMRN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed rare disease biotechnology company, BioMarin files periodic and current reports that describe its financial condition, results of operations, governance changes and material corporate events.
Investors researching BMRN can review Forms 10-K and 10-Q for detailed discussions of BioMarin’s business, risk factors, rare disease portfolio and pipeline strategy. Current reports on Form 8-K, such as those announcing quarterly results, acquisitions, leadership changes or guidance updates, give insight into significant developments affecting the company’s Enzyme Therapies, Skeletal Conditions and gene therapy franchises.
Through this page, users can also track information that may appear in proxy materials and other filings, including board composition and committee appointments, executive roles and the company’s use of non-GAAP financial measures like Non-GAAP Operating Margin and Non-GAAP Diluted EPS, as described in its disclosures. For those monitoring corporate actions, merger agreements, or business development transactions, the related 8-K filings and exhibits are a primary source of official information.
Stock Titan enhances these filings with AI-powered summaries that explain key points in plain language, helping readers interpret long or technical documents. Real-time updates from EDGAR, combined with structured access to forms such as 10-K, 10-Q and 8-K, allow investors to follow BioMarin’s regulatory reporting history and understand how management communicates strategy, performance and risk to the market.
BioMarin Pharmaceutical Inc. completed its previously announced acquisition of Amicus Therapeutics, buying all Amicus shares for $14.50 in cash per share, implying total equity value of about $4.8 billion. Amicus now operates as a wholly owned subsidiary.
To fund the cash deal, BioMarin entered into new senior secured credit facilities consisting of a $2.0 billion Term Loan B, a $800.0 million Term Loan A, and a $600.0 million revolving credit facility, alongside its previously issued 5.500% Senior Notes due 2034 and cash on hand. The term loans were fully drawn at closing, while the revolver remains available for working capital and general corporate purposes.
The new credit agreement is secured by a first‑priority lien on substantially all assets of BioMarin and certain subsidiaries and includes financial covenants, including a Total Net Leverage Ratio cap of 3.50 to 1.00 (temporarily 4.00 to 1.00 in some acquisition scenarios) and a minimum Interest Coverage Ratio of 3.00 to 1.00. With Amicus, BioMarin adds marketed rare‑disease therapies Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease, plus U.S. rights to late‑stage candidate DMX‑200 for focal segmental glomerulosclerosis.
BioMarin Pharmaceutical Inc. completed its previously announced acquisition of Amicus Therapeutics, buying all Amicus shares for $14.50 in cash per share, implying total equity value of about $4.8 billion. Amicus now operates as a wholly owned subsidiary.
To fund the cash deal, BioMarin entered into new senior secured credit facilities consisting of a $2.0 billion Term Loan B, a $800.0 million Term Loan A, and a $600.0 million revolving credit facility, alongside its previously issued 5.500% Senior Notes due 2034 and cash on hand. The term loans were fully drawn at closing, while the revolver remains available for working capital and general corporate purposes.
The new credit agreement is secured by a first‑priority lien on substantially all assets of BioMarin and certain subsidiaries and includes financial covenants, including a Total Net Leverage Ratio cap of 3.50 to 1.00 (temporarily 4.00 to 1.00 in some acquisition scenarios) and a minimum Interest Coverage Ratio of 3.00 to 1.00. With Amicus, BioMarin adds marketed rare‑disease therapies Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease, plus U.S. rights to late‑stage candidate DMX‑200 for focal segmental glomerulosclerosis.
BioMarin Pharmaceutical Inc. reports that France’s Ministry of Economics and Finance has granted foreign direct investment clearance for its planned merger with Amicus Therapeutics. This French FDI clearance satisfies the final outstanding regulatory condition under the Merger Agreement, aside from items to be completed at closing.
The merger, in which Amicus will become a wholly owned subsidiary of BioMarin, is expected to close on April 27, 2026. The companies caution that this timing and other expectations are forward-looking and subject to risks described in their SEC filings and the Amicus merger proxy.
BioMarin Pharmaceutical Inc. is asking stockholders to elect ten directors, ratify KPMG as auditor, approve executive pay on an advisory basis, and approve an amendment increasing shares reserved under the 2017 Equity Incentive Plan at its June 2, 2026 virtual annual meeting.
The proxy highlights 2025 revenue of $3.2 billion, up 13%, with VOXZOGO reaching $927 million. It describes an all-cash agreement to acquire Amicus Therapeutics for about $4.8 billion and the completed $270 million acquisition of Inozyme Pharma. The Board chair role will transition from Richard A. Meier to Ian T. Clark.
BioMarin Pharmaceutical Inc Schedule 13G/A (Amendment No. 12) updates The Vanguard Group's reporting following an internal realignment. The filing states amount beneficially owned: 0 and percent of class: 0%. The Vanguard Group explains certain subsidiaries will report separately in reliance on SEC Release No. 34-39538 dated January 12, 1998.
The filing is signed by Ashley Grim, Head of Global Fund Administration, with a signature date of 03/26/2026.
BioMarin Pharmaceutical executive George Eric Davis, EVP and Chief Legal Officer, reported a routine share disposition related to taxes. On this date, 1,273 shares of common stock were withheld to cover tax obligations at $56.05 per share. After this tax-withholding transaction, he directly holds 78,560 shares of BioMarin common stock, indicating he retains a substantial equity position and that the filing reflects a compensation-related event rather than an open-market sale.
BioMarin Pharmaceutical EVP and Chief Technical Officer Charles Greg Guyer reported a tax-related share disposition. On the transaction date, 1,693 shares of common stock were withheld at a price of $56.05 per share to cover tax obligations, a non‑market transaction. After this event, he directly held 84,140 common shares.
BioMarin Pharmaceutical EVP and CFO Brian Mueller reported a tax-related share disposition. On March 17, 2026, 2,117 shares of common stock were withheld at $56.05 per share to cover tax obligations. After this transaction, he directly holds 123,314 common shares, indicating a routine, non–market sale event.
BioMarin Pharmaceutical Chief Executive Officer Alexander Hardy reported a routine share disposition related to taxes. On March 17, 2026, 4,252 shares of common stock were withheld at $56.05 per share to cover tax obligations. After this transaction, he directly held 214,635 shares.
BioMarin Pharmaceutical EVP and Chief Commercial Officer Cristin Hubbard reported compensation-related equity grants and a small tax withholding transaction. On March 16, 2026, she received 15,410 shares of Common Stock as restricted stock units and a stock option for 36,680 shares of Common Stock at an exercise price of $57.43 per share. The option grant vests 12/48ths on March 16, 2027, with the remaining 36/48ths vesting in equal monthly installments of 1/48th on the 16th day of each month thereafter.
On March 17, 2026, 1,245 shares of Common Stock were disposed of at $56.05 per share in a tax-withholding transaction to satisfy tax obligations, rather than an open-market sale. After these transactions, Hubbard directly held 44,790 shares of BioMarin Common Stock.